[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623434":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":26,"responsibleParty":171,"collaborators":11,"id":173,"slug":174,"hasResults":175,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":11,"eligibilityCriteria":179,"healthyVolunteers":175,"sex":180,"minAge":181,"maxAge":11,"enrollmentInfo":182,"targetDuration":11,"studyType":185,"phases":186,"briefSummary":189,"conditions":190,"keywords":11,"overallStatus":126,"whyStopped":11,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"Hutchmed","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A(Phase I) Dose Escalation","EXPERIMENTAL",null,[13],"Drug: HMPL-A580",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B(Phase IIa) Dose Expansion\u002FDose Optimization",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","HMPL-A580","Part A(Phase I) Dose Escalation Enrolled participants will receive HMPL-A580 treatment in a dose escalation setting initially at 6 predefined dose levels.",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"Part B(Phase IIa) Dose Expansion\u002FDose Optimization Evaluate the safety and preliminary anti-tumor activity of HMPL-A580 in selected solid tumors.",[15],[27,47,62,72,85,100,113,124,138,149,160],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University of California Irvine Medical Center","NOT_YET_RECRUITING","Orange","California","92868","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-117.85311,33.78779,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":45,"phoneExt":11,"email":46},"Zhaohui Liao Arter","CONTACT","714-456-6244","zarter@hs.uci.edu",{"facility":48,"status":29,"city":49,"state":50,"zip":51,"country":33,"countryCode":34,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"BRCR Global","Plantation","Florida","33324",{"type":36,"coordinates":53},[54,55],-80.23184,26.13421,{"lat":55,"lon":54},[58],{"name":59,"role":44,"phone":60,"phoneExt":11,"email":61},"Sumit Sawhney","561-447-0614","ssawhney.md@brcrglobal.com",{"facility":63,"status":29,"city":49,"state":50,"zip":51,"country":33,"countryCode":34,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Florida Clinical Trials Group LLC (Plantation)",{"type":36,"coordinates":65},[54,55],{"lat":55,"lon":54},[68],{"name":69,"role":44,"phone":70,"phoneExt":11,"email":71},"Harshad Amin","772-297-3057","harshamin@floridactg.com",{"facility":73,"status":29,"city":74,"state":50,"zip":75,"country":33,"countryCode":34,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Florida Clinical Trials Group LLC (Tamarac)","Tamarac","33319",{"type":36,"coordinates":77},[78,79],-80.24977,26.21286,{"lat":79,"lon":78},[82],{"name":83,"role":44,"phone":70,"phoneExt":11,"email":84},"Chintan Gandhi","cgandhi@floridactg.com",{"facility":86,"status":29,"city":87,"state":88,"zip":89,"country":33,"countryCode":34,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"University of Washington\u002FFred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":36,"coordinates":91},[92,93],-122.33207,47.60621,{"lat":93,"lon":92},[96],{"name":97,"role":44,"phone":98,"phoneExt":11,"email":99},"Lei Deng","206-606-7017","ldeng1@fredhutch.org",{"facility":101,"status":29,"city":102,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Hunan Cancer Hospital","Changsha","China","CN",{"type":36,"coordinates":106},[107,108],112.97087,28.19874,{"lat":108,"lon":107},[111],{"name":112,"role":44,"phone":11,"phoneExt":11,"email":11},"Yongchang Zhang",{"facility":114,"status":29,"city":115,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Guangxi Medical University Cancer Hospital","Nanning",{"type":36,"coordinates":117},[118,119],108.31667,22.81667,{"lat":119,"lon":118},[122],{"name":123,"role":44,"phone":11,"phoneExt":11,"email":11},"Song Qu",{"facility":125,"status":126,"city":127,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Shanghai East Hospital","RECRUITING","Shanghai",{"type":36,"coordinates":129},[130,131],121.45806,31.22222,{"lat":131,"lon":130},[134],{"name":135,"role":44,"phone":136,"phoneExt":11,"email":137},"Caichun Zhou","86021-58822171","caicunzhoudr@163.com",{"facility":139,"status":29,"city":140,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":141,"geoPoint":145,"contacts":146},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan",{"type":36,"coordinates":142},[143,144],114.26667,30.58333,{"lat":144,"lon":143},[147],{"name":148,"role":44,"phone":11,"phoneExt":11,"email":11},"Kunyu Yang",{"facility":150,"status":29,"city":151,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"The First Affiliated Hospital of Xiamen University","Xiamen",{"type":36,"coordinates":153},[154,155],118.08187,24.47979,{"lat":155,"lon":154},[158],{"name":159,"role":44,"phone":11,"phoneExt":11,"email":11},"Feng Ye",{"facility":161,"status":29,"city":162,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Henan Cancer Hospital","Zhengzhou",{"type":36,"coordinates":164},[165,166],113.64861,34.75778,{"lat":166,"lon":165},[169],{"name":170,"role":44,"phone":11,"phoneExt":11,"email":11},"Suxia Luo",{"type":172,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623434","phase-1-hmpl-a580-in-participants-with-advanced-or-metastatic-solid-tumor-100623434",false,"NCT07396584","HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","A Phase I\u002FⅡa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Understood this study and are able to voluntarily sign the informed consent form (ICF);\n2. Male or Female, Age ≥ 18 years;\n3. Histological confirmed, unresectable, advanced or metastatic solid tumor\n4. Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1\n5. Life expectancy ≥ 12 weeks\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n\nExclusion Criteria:\n\n1. An established diagnosis of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus\n2. Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug\n3. Major surgery within 28 days prior to the first dose of study drug\n4. Active infection requiring systemic treatment\n5. Participant has received a live within 3 months before study enrollment\n6. History of inflammatory gastrointestinal diseases\n7. Known hypersensitivity to any component of HMPL-A580\n8. Pregnant (positive pregnancy test) or lactating;","ALL","18 Years",{"count":183,"type":184},186,"ESTIMATED","INTERVENTIONAL",[187,188],"PHASE1","PHASE2","This is a first-in-human, multicenter, open-label, phase I\u002FⅡa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.",[191],"Solid Tumors, Adult","2026-03-24",{"date":194,"type":195},"2026-03-27","ACTUAL",{"date":197,"type":184},"2026-03-04",{"date":199,"type":184},"2029-01-30",{"name":5,"class":6},11]